| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/24/2003 | US20030077335 Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
| 04/24/2003 | US20030077333 Diarrhea therapy; gel mouth rehydration solution |
| 04/24/2003 | US20030077332 Wound healing agents; viricides |
| 04/24/2003 | US20030077331 Calcium glutarate supplement and phosphorus binder |
| 04/24/2003 | US20030077329 Composition of and method for preparing stable particles in a frozen aqueous matrix |
| 04/24/2003 | US20030077327 Highly compressible ethylcellulose for tableting |
| 04/24/2003 | US20030077325 Mixture of drug and hydrophilic polymer; water solubility |
| 04/24/2003 | US20030077323 Amoxicillin - clarithromycin antibiotic composition |
| 04/24/2003 | US20030077322 Solid dispersion system of pranlukast with improved dissolution and method for preparing the same |
| 04/24/2003 | US20030077321 Complex containing tannin; solid dosage form; sustained release |
| 04/24/2003 | US20030077320 Hydrocodone therapy |
| 04/24/2003 | US20030077317 Drug delivery; adhesion to mucous membranes; biopolymer |
| 04/24/2003 | US20030077316 Patch containing drug; flexible backing; pressure sensitive adhesive |
| 04/24/2003 | US20030077313 Anti-stress composition intended for incorporation mainly in nutritional vehicles |
| 04/24/2003 | US20030077308 Topical compositions for veterinary uses |
| 04/24/2003 | US20030077305 Administering to a mammal a formualtion comprising cationic lipids/DNA complex, allowing the complex to associate with angiogenic endothelial cells of an angiogenic blood vessel for a time such that the complex enters the target cells |
| 04/24/2003 | US20030077303 Consists of naproxen, a butyl spacer and a nitrogen oxide (NO)-releasing nitrate group, linked together into a single molecule; useful as antiinflammatory agent and an analgesic |
| 04/24/2003 | US20030077302 An ophthalmic formulation for glaucoma treatment in the form of a suspension gel containing the free acid of diclofenamide, preservatives, gel forming agent and agents to adjust the pH |
| 04/24/2003 | US20030077301 Topically administering to a localized region affected by the inflammatory dermatosis on a patient skin a formulation containing a active agent,and a permeation enhancing base to enhance the flux of active agent through skin without damage |
| 04/24/2003 | US20030077300 Pharmaceutical drug delivery applicator for the intranasal adminstration of narcotic drugs (controlled substances) such as morphine and derivatives for acute pain management through pharmaceutical intervention |
| 04/24/2003 | US20030077298 Activators and ligands of PPAR-beta/delta for the treatment of skin conditions |
| 04/24/2003 | US20030077297 Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| 04/24/2003 | US20030077296 Gels for topical application to female genitalia include propylene glycol a humectant solvent; aloe barbadensis leaf juice as skin-conditioner, hydroxyethylcellulose binder, menthol an analgesic stimulant, methylpraban, ginseng root |
| 04/24/2003 | US20030077294 Proteinaceous material associated with adenylate cyclase activity in cultures of Bordetella pertussis; useful as components of acellular whooping cough vaccines |
| 04/24/2003 | US20030077275 Chimeric antibody specific to human CD4 which comprises the variable heavy and light chain sequences of an Old World monkey monoclonal antibody produced against human CD4 and human constant heavy and light domain sequences |
| 04/24/2003 | US20030077262 Methods and compositions for modulating apoptosis |
| 04/24/2003 | US20030077253 Implantable or insertable therapeutic agent delivery device |
| 04/24/2003 | US20030077249 DNA coding for one or more recombinant chimeric receptors comprising two or more different cytoplasmic signalling polypeptides; drug delivery system for treating cancer |
| 04/24/2003 | US20030077246 TNFr/OPG-like molecules and uses thereof |
| 04/24/2003 | US20030077245 A polyalkylene oxide-ethylene oxide block copolymer as antigrowth agents |
| 04/24/2003 | US20030077244 A biocompatible crosslinking polymer comprising acrylamide and methylene bis-acrylamide; medical procedure involves injection of polyacrylamide gel under the mucous membrane |
| 04/24/2003 | US20030077243 Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
| 04/24/2003 | US20030077242 Methods for forming regional tissue adherent barriers and drug delivery systems |
| 04/24/2003 | US20030077239 Composition for the antidandruff treatment of the hair and scalp based on an antidandruff active principle and on a hydroxy acid |
| 04/24/2003 | US20030077230 Container equipped with a metering valve and containing a pressurized formulation of beta-agonist drug, a fluoroalkane propellant and > 5% of a solvent |
| 04/24/2003 | US20030077229 Aqueous polar solvent, active compound, and flavoring agents; propellant-free |
| 04/24/2003 | US20030077228 Polar solvent 30-99.69%, active compound 0.001-60%, and f lavoring agent 0.1-10%; propellant free |
| 04/24/2003 | US20030077227 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| 04/24/2003 | US20030075470 Transdermal/transmucosal patch packaging |
| 04/24/2003 | US20030075187 Mixed chimerism and tolerance |
| 04/24/2003 | US20030075172 Method and apparatus for dispensing inhalator medicament |
| 04/24/2003 | DE20301069U1 Composition for treating type II diabetes by activating insulin naturally present in the body, comprises petroleum and spirit vinegar, preferably diluted with water |
| 04/24/2003 | CA2781766A1 Method of stabilizing reduced coenzyme q10 |
| 04/24/2003 | CA2746795A1 Method for crystallizing reduced coenzyme q10 |
| 04/24/2003 | CA2722197A1 Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
| 04/24/2003 | CA2684419A1 Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity |
| 04/24/2003 | CA2494706A1 Chimeric glycosylphosphatidylinositol containing peptides |
| 04/24/2003 | CA2466889A1 Use of the adenoviral e2 late promoter |
| 04/24/2003 | CA2466800A1 Modulation of ocular growth and myopia by gaba drugs |
| 04/24/2003 | CA2466082A1 Anti-microbial composition comprising a metal ion chelating agent |
| 04/24/2003 | CA2464412A1 Tetracyclic azaindoles and -indolines having serotonin 5-ht2cactivity |
| 04/24/2003 | CA2463996A1 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 04/24/2003 | CA2463991A1 Therapeutic composition and use |
| 04/24/2003 | CA2463911A1 Tumor targeted photodiagnostic-phototherapeutic agents |
| 04/24/2003 | CA2463898A1 Methods and materials for targeting and affecting selected cells |
| 04/24/2003 | CA2463771A1 Oligoamine compounds and derivatives thereof for cancer therapy |
| 04/24/2003 | CA2463769A1 Composition and method for treating diabetes |
| 04/24/2003 | CA2463754A1 Concomitant oral and topical administration of anti - infective agents |
| 04/24/2003 | CA2463729A1 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors |
| 04/24/2003 | CA2463724A1 Organosulfur inhibitors of tyrosine phosphatases |
| 04/24/2003 | CA2463711A1 Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity |
| 04/24/2003 | CA2463687A1 Cyclodextrin complexes |
| 04/24/2003 | CA2463686A1 Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them |
| 04/24/2003 | CA2463685A1 Novel .beta.-phenyl-.alpha.-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds |
| 04/24/2003 | CA2463682A1 Method of reducing type 2 diabetes in high risk patients |
| 04/24/2003 | CA2463674A1 Controlled release capsules for providing both pulsed burst and controlled release of drugs to the rumen of ruminant animals over an extended time period |
| 04/24/2003 | CA2463655A1 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| 04/24/2003 | CA2463641A1 Antisense antiviral agent and method for treating ssrna viral infection |
| 04/24/2003 | CA2463628A1 Himbacine analogues as thrombin receptor antagonists |
| 04/24/2003 | CA2463624A1 Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications |
| 04/24/2003 | CA2463597A1 Rosuvastatin in pre demented states |
| 04/24/2003 | CA2463579A1 Treatment of cns disorders using cns target modulators |
| 04/24/2003 | CA2463571A1 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto |
| 04/24/2003 | CA2463518A1 Carbinols for the treatment of neuropathic dysfunction |
| 04/24/2003 | CA2463509A1 Lactam derivatives as antagonists for human 11cby receptors |
| 04/24/2003 | CA2463508A1 Pyrimidinones as melanin concentrating hormone receptor 1 |
| 04/24/2003 | CA2463492A1 Methods for the treatment of carcinoma |
| 04/24/2003 | CA2463469A1 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes |
| 04/24/2003 | CA2463459A1 Novel use of pulmonary surfactant |
| 04/24/2003 | CA2463435A1 Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma |
| 04/24/2003 | CA2463426A1 Substituted piperazine cyclohexane carboxilic acid amides and the use thereof |
| 04/24/2003 | CA2463395A1 Therapeutic agents for low hdl-cholesterolemia |
| 04/24/2003 | CA2463159A1 Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors |
| 04/24/2003 | CA2463142A1 Methods for preventing and treating bone loss with steroid compounds |
| 04/24/2003 | CA2463020A1 Use of gp130 activators in diabetic neuropathy |
| 04/24/2003 | CA2463016A1 Composition comprising paracetamol and a bitterness masking component |
| 04/24/2003 | CA2462980A1 Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
| 04/24/2003 | CA2462514A1 Dicarboxylic acid derivatives, their preparation and therapeutical use |
| 04/24/2003 | CA2462442A1 Alkyne matrix metalloproteinase inhibitors |
| 04/24/2003 | CA2462441A1 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
| 04/24/2003 | CA2462219A1 Pharmaceutical formulation comprising (r) -bicalutamide |
| 04/24/2003 | CA2462147A1 Bicyclic oxopyridine and oxopyrimidine derivatives |
| 04/24/2003 | CA2461818A1 Treatment and diagnosis of insulin resistant states |
| 04/24/2003 | CA2461758A1 Use of cystathionine |
| 04/24/2003 | CA2461556A1 Compositions and methods for delivery of microparticles of poorly water soluble drugs and methods of treatment |
| 04/24/2003 | CA2461550A1 Stabilized compositions of aqueous reduced coenzyme q solution |
| 04/24/2003 | CA2461542A1 Gap junctions and endothelial-derived hyperpolarizing factor (edhf) |
| 04/24/2003 | CA2461170A1 Peptidyl ketones as inhibitors of dpiv |
| 04/24/2003 | CA2461168A1 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline |
| 04/24/2003 | CA2460574A1 Enteric coated tablets comprising mycophenolic acid or mycophenolate salt |